Cyclopeptamine lipopeptide antifungal agents

Bibliography

• BENZ F, KNUSEL F, NUESCH J et al.: Stoffwechselpro-ducte von mikroorganismen. Echinocandin B, ein-neuartigies polypeptid-antibioticum aus Aspergillus nidulans var. echinulatus. Helv. Chim. Acta (1974) 57:2459–2477.
   Google Scholar
• HAMMOND ML: Chemical and structure activity studies of echinocandin lipopeptides. In: Cutaneous Antifungal Agents. Rippon JW, Fromtling RA (Eds.), Marcel Deccer, New York, USA (1993).
   Google Scholar
• ••A detailed review of echinocandin class of natural products:isolation and SAR.
   Google Scholar
• SCHMATZ DM: The use of B-1,3-glucan synthesis inhibitors for the treatment and prevention of Pneumocystis carinii pneumonia. In: Pneumocystis carinii. Walzer PD (Ed.), Marcel Dekker, New York, USA (1994).
   Google Scholar
• TRAXLER P, FRITZ H, FUHRER H, RICHTER WJ: Papula-candins, a new family of antibiotics with antifungal ac-tivity. Structures of papulacandins A, B, C and D. J. Antibiot. (1980) 33:967–978.
   PubMed Web of Science ®Google Scholar
• TAFT CS, SELITRENNIKOFF CP: Cilofungin inhibition of 13-1,3-glucan synthase: the lipophilic sidechain is es-sential for inhibition for enzyme activity. J. Antibiot. (1990) 43:433–437.
   PubMed Web of Science ®Google Scholar
• ••This paper reports the ability of fatty acid side-chains to in-hibit 13- (1,3)-glucan synthase.
   Google Scholar
• BALKOVEC JM: Lipopeptide antifungal agents. Exp. Opin. Invest. Drugs (1994) 3:65–82.
   Google Scholar
• ••A review of aureobasidins and echinocandins antifungalagents.
   Google Scholar
• MUKHOPADHYAY T, GANGULY BN, FEHLHABER HW et Mulundocandin, a new lipopeptide antibiotic 1. Taxonomy, fermentation, isolation and characteriza-tion. J. Antibiot. (1987) 50:275–280.
   Google Scholar
• MUKHOPADHYAY T, GANGULY BN, ROY K et al.: Mulun-docandin, a new lipopeptide antibiotic II. Structure elucidation. J. Antibiot. (1987) 50:281–289.
   Google Scholar
• RODRIGUEZ MJ, HITCHCOCK SA: Antiftmgal patents ap-pearing from June 1995 to June 1997. Exp. Opin. Ther. Patents (1997) 7:829–841.
   Web of Science ®Google Scholar
• ••A thorough and timely report on several classes of antifungalagents developed by the pharmaceutical industries. The re-port also talks about their mode of action.
   Google Scholar
• LARTEY PA: Approaches to new leads in fungal cell wall inhibition. 3rd International Antifungal Drug Discover)/ Summit. Princeton, New Jersey (March 26–27, 1997).
   Google Scholar
• ••First report of cylopeptamines as an antifungal agent.
   Google Scholar
• CAPOBIANCO JO, ZAKULA D, FROST DJ et al.: Cellular accumulation, localization and activity of a synthetic cy-clopeptamine in fungi. Antimicrob. Agents Chemother. (1998) 42:389–393.
   PubMed Web of Science ®Google Scholar
• •A report on cellular biology of the synthetic cyclopeptamine A172013 in fungi.
   Google Scholar
• LARTEY PA, MOEHLE CM: Recent advances in antifungal agents. Ann. Reports Med. Chem. (1997) 32:151–160.
   Web of Science ®Google Scholar
• •Most recent review on different classes of antifungal agents and targets.
   Google Scholar
• DEBONO M, ABBOTT BJ, BARNHART M et al.: Synthesis of new analogs of echinocandin B by enzymatic deacy-lation and chemical reacylation of the echinocandin B peptide: synthesis of the antifungal agent ciloftmgin (LY 121019). J. Antibiot. (1989) 52:389–397.
   Google Scholar
• ••This paper describes the first enzymatic cleavage of the resi-dent lipophilic side-chain of cilofungin to get echinocandin B-nucleus. It also reports the reacylation and SAR study with different side-chains.
   Google Scholar
• DEBONO M, TURNER WW, RODRIGUEZ MJ et al: Semi synthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J. Med. Chem. (1995) 38:3271–3281.
   PubMed Web of Science ®Google Scholar
• ••A complete description of the synthesis and antifungal activ-ity for the echinocandin B side-chain SAR.
   Google Scholar
• BARTIZAL K: The discovery and development of Merck's pneumocandin antifungal L-743872: a human clinical development candidate. 3rd International Anti-fungal Drug Discovery Summit. Princeton, New Jersey (March 26–27, 1997).
   Google Scholar
• KUROKAWA N, OHFUNE Y: Total synthesis of echino-candins. 1. Stereocontrolled syntheses of the constitu-ents amino acids. J. Am. Chem. Soc. (1986) 108:6041–6045.
   PubMed Web of Science ®Google Scholar
• •Report of first total synthesis of echinocandin D.
   Google Scholar
• EVANS DA, WEBER AE: Synthesis of cyclic hexapeptide echinocandin D. New approaches to the asymmetric synthesis of p-hydroxy a-amino acids Stereocon-trolled syntheses of the constituents amino acids. J. Am. Chem. Soc. (1987) 109:7151–7157.
   Google Scholar
• •Second total synthesis of echinocandin D, report of new methodology.
   Google Scholar
• ZAMBIAS RA, HAMMOND ML, HECK JV et al.: Preparation and structure activity relationships of simplified ana-logues of the antifungal agents ciloftmgin: a total syn-thesis approach. J. Med. Chem. (1992) 35:2843–2855.
   PubMed Web of Science ®Google Scholar
• ••The first solid phase total synthesis of lipopeptide antibiot-ics. Minimum fungicidal concentrations (MFCs) on several analogues were reported.
   Google Scholar
• GEORGOPAPADAKOU NH: Antiftmgals targeted to the cell wall. Exp. Opin. Invest. Drugs (1997) 6:147–150.
   PubMedGoogle Scholar
• •A report of the worldwide market for antifungal drugs.
   Google Scholar
• TURNER WW, RODRIGUEZ MJ: Recent advances in the medicinal chemistry of antifungal agents. Curr. Pharm. Design (1996) 27:209–224.
   Google Scholar